Stereotactic radiosurgery for patients with spinal metastases from prostate cancer.

Ahead of Print

Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE

Publication: 2005- : New York : Springer
Original Publication: Boston : M. Nijhoff, 1983-

Purpose: Spinal metastases may result in intractable pain, neurological deficit, and vertebral body collapse. There are only a few studies describing outcomes following spine stereotactic radiosurgery (SRS) specifically for prostate cancer metastases.
Methods: A prospectively collected database of patients with prostate cancer spinal metastases treated at the University of Pittsburgh Medical Center from 2003 to 2023 was analyzed. The primary outcome was local control (LC). Secondary outcomes were overall survival (OS), pain resolution, and adverse radiation effects (AREs).
Results: Thirty-seven patients and 51 lesions were identified. Fifteen lesions (29%) were previously resected and 34 lesions (67%) were previously irradiated. The median tumor volume was 37.0 cc (range: 2.9-263.3). A majority of lesions (71%) were treated in a single fraction (median 20 Gy, range: 14-22.5); multi-fractionated treatment consisted of 21-30 Gy in 2-5 fractions. Median follow-up was 12 months (range: 1-146). The 6-month, 1-year, and 2-year LC rates were 97%, 91%, and 91%, respectively. No tested prognostic factors were associated with LC, including hormone sensitivity. The 6-month, 1-year, and 2-year OS rates were 71%, 56%, and 32%; age > 70 years (p = 0.048) and tumor volume > 30 cc (p = 0.03) were associated with inferior rates of OS. Complete or partial pain response was observed in 58% of patients. There were 8 instances (16%) of AREs, 2 of which were vertebral compression fractures (4%).
Conclusion: Radiosurgery as a primary or adjuvant treatment modality for prostate cancer spinal metastases confers durable LC and moderate pain relief with minimal toxicity. Further studies are warranted to optimize management in this patient population.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Leslie SW, Soon-Sutton TL, Sajjad RIA, Skelton H (2024) WP. Prostate Cancer StatPearls.
Alukal JP, Lepor H (2016) Testosterone Deficiency and the prostate. Urol Clin North Am May 43(2):203–208. https://doi.org/10.1016/j.ucl.2016.01.013. (PMID: 10.1016/j.ucl.2016.01.013)
Pan C, He Y, Wang H et al (2023) Identifying patients with Rapid Progression from hormone-sensitive to castration-resistant prostate Cancer: a retrospective study. Mol Cell Proteom Sep 22(9):100613. https://doi.org/10.1016/j.mcpro.2023.100613. (PMID: 10.1016/j.mcpro.2023.100613)
Bubendorf L, Schopfer A, Wagner U et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol May 31(5):578–583. https://doi.org/10.1053/hp.2000.6698. (PMID: 10.1053/hp.2000.6698)
Chohan MO, Kahn S, Cederquist G et al (2018) Surgical Decompression of High-Grade Spinal Cord Compression from Hormone Refractory Metastatic Prostate Cancer. Neurosurgery. May 1.;82(5):670–677. https://doi.org/10.1093/neuros/nyx292.
Williams BJ, Fox BD, Sciubba DM et al (2009) Surgical management of prostate cancer metastatic to the spine. J Neurosurg Spine May 10(5):414–422. https://doi.org/10.3171/2009.1.SPINE08509. (PMID: 10.3171/2009.1.SPINE08509)
Meng T, Chen R, Zhong N et al (2016) Factors associated with improved survival following surgical treatment for metastatic prostate cancer in the spine: retrospective analysis of 29 patients in a single center. World J Surg Oncol Jul 29(1):200. https://doi.org/10.1186/s12957-016-0961-y. (PMID: 10.1186/s12957-016-0961-y)
Chen JJ, Sullivan AJ, Shi DD et al (2021) Characteristics and predictors of Radiographic Local Failure in patients with spinal metastases treated with Palliative Conventional Radiation Therapy. Adv Radiat Oncol May-Jun 6(3):100665. https://doi.org/10.1016/j.adro.2021.100665. (PMID: 10.1016/j.adro.2021.100665)
Gao ZY, Zhang T, Zhang H, Pang CG, Jiang WX (2020) Prognostic factors for overall survival in patients with spinal metastasis secondary to prostate cancer: a systematic review and meta-analysis. BMC Musculoskelet Disord Jun 17(1):388. https://doi.org/10.1186/s12891-020-03412-0. (PMID: 10.1186/s12891-020-03412-0)
Lee CC, Tey J, Cheo T et al (2023) Outcomes of patients with spinal metastases from prostate Cancer treated with conventionally-fractionated External Beam Radiation Therapy. Global Spine J Mar 13(2):284–294. https://doi.org/10.1177/2192568221994798. (PMID: 10.1177/2192568221994798)
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin Nov 68(6):394–424. https://doi.org/10.3322/caac.21492. (PMID: 10.3322/caac.21492)
Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet May 18(10185):2051–2058. https://doi.org/10.1016/S0140-6736(18)32487-5. (PMID: 10.1016/S0140-6736(18)32487-5)
Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or Metastasis-Directed therapy for oligometastatic prostate Cancer recurrence: a prospective, randomized, Multicenter Phase II Trial. J Clin Oncol Feb 10(5):446–453. https://doi.org/10.1200/JCO.2017.75.4853. (PMID: 10.1200/JCO.2017.75.4853)
Phillips R, Shi WY, Deek M et al (2020) Outcomes of Observation vs Stereotactic Ablative Radiation for oligometastatic prostate Cancer: the ORIOLE phase 2 Randomized Clinical Trial. JAMA Oncol May 1(5):650–659. https://doi.org/10.1001/jamaoncol.2020.0147. (PMID: 10.1001/jamaoncol.2020.0147)
Sahgal A, Myrehaug SD, Siva S et al (2021) Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol Jul 22(7):1023–1033. https://doi.org/10.1016/S1470-2045(21)00196-0. (PMID: 10.1016/S1470-2045(21)00196-0)
Deek MP, Taparra K, Dao D et al (2021) Patterns of recurrence and modes of Progression after Metastasis-Directed Therapy in Oligometastatic Castration-sensitive prostate Cancer. Int J Radiat Oncol Biol Phys Feb 1(2):387–395. https://doi.org/10.1016/j.ijrobp.2020.08.030. (PMID: 10.1016/j.ijrobp.2020.08.030)
Fanetti G, Marvaso G, Ciardo D et al (2018) Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases. Med Oncol Apr 18(5):75. https://doi.org/10.1007/s12032-018-1137-0. (PMID: 10.1007/s12032-018-1137-0)
Habl G, Straube C, Schiller K et al (2017) Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer May 22(1):361. https://doi.org/10.1186/s12885-017-3341-2. (PMID: 10.1186/s12885-017-3341-2)
Gerszten PC, Burton SA, Ozhasoglu C, Welch WC (1976) Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa Jan 15 2007;32(2):193-9. https://doi.org/10.1097/01.brs.0000251863.76595.a2.
Cox BW, Spratt DE, Lovelock M et al (2012) International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys Aug 1(5):e597–605. https://doi.org/10.1016/j.ijrobp.2012.03.009. (PMID: 10.1016/j.ijrobp.2012.03.009)
Tseng CL, Eppinga W, Charest-Morin R et al (2017) Spine stereotactic body radiotherapy: indications, outcomes, and points of caution. Global Spine J Apr 7(2):179–197. https://doi.org/10.1177/2192568217694016. (PMID: 10.1177/2192568217694016)
Abugharib A, Zeng KL, Tseng CL et al (2022) Spine stereotactic body radiotherapy for prostate Cancer metastases and the impact of hormone sensitivity status on local control. Neurosurg Jun 1(6):743–749. https://doi.org/10.1227/neu.0000000000001909. (PMID: 10.1227/neu.0000000000001909)
Beckham TH, Rooney MK, Cifter G et al Stereotactic radiosurgery for prostate cancer spine metastases: local control and fracture risk using a simultaneous integrated boost approach. J Neurosurg Spine Jun 14 2024:1–9. https://doi.org/10.3171/2024.3.SPINE24157.
Wang JZ, Guerrero M, Li XA (2003) How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys Jan 1(1):194–203. https://doi.org/10.1016/s0360-3016(02)03828-2. (PMID: 10.1016/s0360-3016(02)03828-2)
Bilsky MH, Laufer I, Fourney DR et al (2010) Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine Sep 13(3):324–328. https://doi.org/10.3171/2010.3.SPINE09459. (PMID: 10.3171/2010.3.SPINE09459)
Fourney DR, Frangou EM, Ryken TC et al (2011) Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol Aug 1(22):3072–3077. https://doi.org/10.1200/JCO.2010.34.3897. (PMID: 10.1200/JCO.2010.34.3897)
Hurley P, Azzopardi C, Botchu R, Grainger M, Gardner A (2021) Can MRI be used as a safe and expedient option for calculating spinal instability neoplastic score for patients with metastatic spinal cord compression? Bone Joint J May 103–B(5):971–975. https://doi.org/10.1302/0301-620X.103B5.BJJ-2020-1823.R1. (PMID: 10.1302/0301-620X.103B5.BJJ-2020-1823.R1)
Gerszten PC, Burton SA, Ozhasoglu C (2007) CyberKnife radiosurgery for spinal neoplasms. Prog Neurol Surg 20:340–358. https://doi.org/10.1159/000100177. (PMID: 10.1159/00010017717318002)
Taori S, Adida S, Tang A et al (2024) Stereotactic radiosurgery for patients with spinal metastases from thyroid Cancer: a 20-Year experience. World Neurosurg Feb 25. https://doi.org/10.1016/j.wneu.2024.02.102.
Taori S, Adida S, Tang A et al (2024) The role of spine stereotactic radiosurgery for patients with breast cancer metastases. J Neurooncol Feb 14. https://doi.org/10.1007/s11060-024-04599-1.
Maccauro G, Spinelli MS, Mauro S, Perisano C, Graci C, Rosa MA (2011) Physiopathology of spine metastasis. Int J Surg Oncol 2011:107969. https://doi.org/10.1155/2011/107969. (PMID: 10.1155/2011/107969223124913265280)
Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res Mar 15(6):1665–1671. https://doi.org/10.1158/1078-0432.CCR-06-0067. (PMID: 10.1158/1078-0432.CCR-06-0067)
Moreira DM, Howard LE, Sourbeer KN et al (2016) Predictors of time to Metastasis in Castration-resistant prostate Cancer. Urol Oct 96:171–176. https://doi.org/10.1016/j.urology.2016.06.011. (PMID: 10.1016/j.urology.2016.06.011)
Cereceda LE, Flechon A, Droz JP (2003) Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. Clin Prostate Cancer Jun 2(1):34–40. https://doi.org/10.3816/cgc.2003.n.010. (PMID: 10.3816/cgc.2003.n.010)
Ju DG, Zadnik PL, Groves ML et al (2013) Factors associated with improved outcomes following decompressive surgery for prostate cancer metastatic to the spine. Neurosurg Oct 73(4):657–666 discussion 666. https://doi.org/10.1227/NEU.0000000000000070. (PMID: 10.1227/NEU.0000000000000070)
Laufer I, Rubin DG, Lis E et al (2013) The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist Jun 18(6):744–751. https://doi.org/10.1634/theoncologist.2012-0293. (PMID: 10.1634/theoncologist.2012-0293)
Zeng KL, Sahgal A, Husain ZA et al (2021) Local control and patterns of failure for Radioresistant spinal metastases following stereotactic body radiotherapy compared to a Radiosensitive reference. J Neurooncol Mar 152(1):173–182. https://doi.org/10.1007/s11060-020-03691-6. (PMID: 10.1007/s11060-020-03691-6)

Keywords: Prostate cancer; Spinal stereotactic radiosurgery; Spine metastasis; Stereotactic radiosurgery; Tumor control

Date Created: 20240924 Latest Revision: 20240924

20240924

10.1007/s11060-024-04821-0

39316317